Attached files
file | filename |
---|---|
10-K - China Yongxin Pharmaceuticals Inc. | v177274_10k.htm |
EX-31.1 - China Yongxin Pharmaceuticals Inc. | v177274_ex31-1.htm |
EX-21.1 - China Yongxin Pharmaceuticals Inc. | v177274_ex21-1.htm |
EX-32.1 - China Yongxin Pharmaceuticals Inc. | v177274_ex32-1.htm |
EX-10.17 - China Yongxin Pharmaceuticals Inc. | v177274_ex10-17.htm |
EX-10.14 - China Yongxin Pharmaceuticals Inc. | v177274_ex10-14.htm |
EX-10.13 - China Yongxin Pharmaceuticals Inc. | v177274_ex10-13.htm |
EX-10.15 - China Yongxin Pharmaceuticals Inc. | v177274_ex10-15.htm |
EX-10.16 - China Yongxin Pharmaceuticals Inc. | v177274_ex10-16.htm |
Exhibit
31.2
CERTIFICATION
I, Harry
Zhang, certify that:
1. I
have reviewed this report on Form 10-K of China Yongxin Pharmaceuticals
Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
4. The
registrant's other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
|
a.
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;
|
|
b.
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
c.
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
d.
|
Disclosed
in this report any change in the registrant's internal financial reporting
that occurred during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the
small business issuer's internal control over the financial reporting;
and
|
5. The
registrant's other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):
|
a.
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information;
and
|
|
b.
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control
over financial reporting.
|
/s/ Harry Zhang
|
Harry
Zhang
Chief
Financial Officer
March
30, 2010
|